Search

Planting Seeds in These Times: Stories of Resistance and Possibility for the HIV Movement

Global Health Watch: PEPFAR Data Reveal Prevention Crisis, Impact of HIV Cuts on South Africa, CDC Blocks COVID-19 Vaccine Report

Newly released PEPFAR data reveals declines in HIV testing and prevention; a new report details the impact of US funding cuts on HIV programs in South Africa; and the US Centers for Disease Control and Prevention (CDC) blocks publication showing the benefits of COVID-19 vaccination adding to further turmoil around US vaccine policy and scientific transparency.

Decline in PEPFAR Supported PrEP

Official characterizations of the HIV response as “doing very good” warrant a closer look at the data. AVAC’s analysis of PEPFAR prevention figures shows PrEP initiations declined 41% in one year, with women and men each seeing drops exceeding 50%. Data on key populations remains unavailable.

Source of Lenacapavir for PrEP Supply to Early Adopter Countries

The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery planned to start in early 2026.

Potential Lenacapavir Supply, 2026-28

Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.

Global Health Watch: LEN for PrEP commitments, US budget cuts shift from basic research, “trade over aid” raises global health concerns

This week, a new commitment to expand the reach of lenacapavir for HIV PrEP is a step forward but not enough to deliver impact, detail on the proposed US budget cuts reflects a shift away from basic research, and a broader shift toward “trade over aid” raises new concerns for global health financing and impact.

Lenacapavir Implementation Studies

Ongoing and planned implementation studies for the lenacapavir as of April 2026.

Three Million is a Step Forward, But Not Enough

In response to the the US State Department, Global Fund, and Gilead announcement of increased volume commitments for lenacapavir (LEN) for HIV prevention, AVAC and Access Bridge call for global leaders to do even more to ensure meaningful, expanded access.

Three Million is a Step Forward, But Not Enough

In response to the the US State Department, Global Fund, and Gilead announcement of increased volume commitments for lenacapavir (LEN) for HIV prevention, AVAC and Access Bridge call for global leaders to do even more to ensure meaningful, expanded access.

Roundup: The latest resources powering HIV & STI advocacy

Advocates are driving progress in HIV and STI prevention—guiding research, expanding access, holding powerful actors accountable and elevating community priorities. This roundup highlights advocacy in action, from new resources and policy frameworks to updates on the rollout of the latest prevention tools.